IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Impact · against what's priced in

Amgen receives a significant catalyst as the unprecedented survival data for IMDELLTRA in first-line SCLC provides a new growth engine independent of the MariTide obesity play. AstraZeneca also benefits from the strong combination data for IMFINZI, though the impact is balanced by the moderate increase in Grade 3+ adverse events.

AMGN+0.70: Not in the price yet
In context: The market is not currently pricing in this first-line expansion for IMDELLTRA, which reduced the risk of death by 58% and extended median OS to 21.1 months. This creates a material revenue driver distinct from the MariTide obesity candidate and the erosion of legacy products like Enbrel.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

What matters in this story

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

What matters in this story

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

How each ticker is affected

Connected tickers

Track these names every morning.

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

What matters in this story

Next reads from the same story arc

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

What matters in this story

Next reads from the same story arc

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

How each ticker is affected

Connected tickers

Track these names every morning.

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors